A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
Inclusion Criteria:
Exclusion Criteria:
Macquarie University, New South Wales 2109, Australia
Jiangsu, 221004, China
Hokkaido, 064-0804, Japan
Nankoku-shi, 783-8509, Japan
Ebdentown, Upper Hutt 5018, New Zealand
Kapiti, 5036, New Zealand
Taoyuan County, 333, Taiwan
Tyne and Wear, NE29 8NH, United Kingdom